ANL

Insider Trades

Name	Value	Action	Price	Current Price
Lu YangDirector, 10 Percent Owner, Officer: CEO $13210 shares SellMay 13, 2026 $13.18 --
Lu YangDirector, CEO, 10% Owner $13210 shares SellMay 13, 2026 $13.18 --

News

zacks.comAdlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Knowzacks.comMay 20

zacks.comHere's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Nowzacks.comMay 11

zacks.comIs ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?zacks.comApr 28

globenewswire.comAdlai Nortye Announces $150.0 Million Private Placement Equity Financingglobenewswire.comApr 16

Trade ANL

About Adlai Nortye Ltd.

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

CEO: Yang Lu
IPO Date: Sep 29, 2023

Market Data

Open: $11.43
High: $11.43
Low: $9.90
Volume: 147.1K
52W High: $17.25
52W Low: $0.879

Valuation

Market Cap: $528M
Enterprise Value: $531M

Financials

Free Cash Flow: $-34M
Revenue: $5.0M
Net Income: $-36M
Cash: $24M
Debt: $26M

Events

EarningsAug 6

EPS est. -0.136